$NRIX
Nurix Therapeutics, Inc.

2023 Q1 Form 10-K Financial Statement

#000154959523000021 Filed on February 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $12.69M $6.783M $38.63M
YoY Change 31.85% -8.29% 29.84%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.821M $9.367M $38.00M
YoY Change 6.43% 6.23% 21.78%
% of Gross Profit
Research & Development $45.82M $46.11M $184.5M
YoY Change 6.21% 26.21% 58.46%
% of Gross Profit
Depreciation & Amortization $1.752M $1.619M $5.349M
YoY Change 76.79% 113.87% 91.72%
% of Gross Profit
Operating Expenses $55.64M $55.47M $222.5M
YoY Change 6.25% 22.32% 50.7%
Operating Profit -$42.95M -$183.9M
YoY Change 0.49% 55.97%
Interest Expense $2.219M $1.973M $3.507M
YoY Change 951.66% 568.81% 326.12%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$40.73M -$46.72M -$180.4M
YoY Change -4.23% 24.06% 54.07%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$40.73M -$46.72M -$180.4M
YoY Change -4.23% 23.91% 53.9%
Net Earnings / Revenue -321.11% -688.74% -466.93%
Basic Earnings Per Share -$0.75 -$3.71
Diluted Earnings Per Share -$0.75 -$0.87 -$3.71
COMMON SHARES
Basic Shares Outstanding 47.27M shares 48.61M shares
Diluted Shares Outstanding 54.03M shares 48.61M shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $276.2M $308.2M $308.2M
YoY Change 5.81% 4.33% 4.33%
Cash & Equivalents $33.57M $64.47M $63.57M
Short-Term Investments $243.6M $244.7M $244.7M
Other Short-Term Assets $12.08M $10.21M $10.21M
YoY Change 7.86% 7.69% 7.69%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $288.3M $318.4M $318.4M
YoY Change 2.8% 2.36% 2.36%
LONG-TERM ASSETS
Property, Plant & Equipment $17.72M $17.16M $29.51M
YoY Change 31.02% 51.35% 16.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $48.45M $63.88M $63.88M
YoY Change -60.83% -53.44% -53.44%
Other Assets $3.841M $4.022M $4.923M
YoY Change -7.6% 41.97% 57.84%
Total Long-Term Assets $81.83M $98.31M $98.31M
YoY Change -47.96% -40.65% -40.65%
TOTAL ASSETS
Total Short-Term Assets $288.3M $318.4M $318.4M
Total Long-Term Assets $81.83M $98.31M $98.31M
Total Assets $370.2M $416.8M $416.8M
YoY Change -15.44% -12.59% -12.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.629M $5.064M $5.064M
YoY Change -6.4% -23.85% -23.85%
Accrued Expenses $20.94M $27.96M $27.96M
YoY Change 24.3% 51.98% 51.98%
Deferred Revenue $38.31M $37.63M
YoY Change -11.3% -8.68%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $64.88M $70.66M $70.66M
YoY Change -1.77% 6.64% 6.64%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $31.22M $42.41M $42.41M
YoY Change -52.51% -37.83% -37.83%
Total Long-Term Liabilities $31.22M $42.41M $42.41M
YoY Change -52.51% -37.83% -37.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $64.88M $70.66M $70.66M
Total Long-Term Liabilities $31.22M $42.41M $42.41M
Total Liabilities $96.10M $113.1M $113.1M
YoY Change -27.09% -15.92% -15.92%
SHAREHOLDERS EQUITY
Retained Earnings -$442.0M -$401.3M
YoY Change 67.81% 81.67%
Common Stock $719.3M $709.3M
YoY Change 25.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $274.1M $303.7M $303.7M
YoY Change
Total Liabilities & Shareholders Equity $370.2M $416.8M $416.8M
YoY Change -15.44% -12.59% -12.59%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$40.73M -$46.72M -$180.4M
YoY Change -4.23% 23.91% 53.9%
Depreciation, Depletion And Amortization $1.752M $1.619M $5.349M
YoY Change 76.79% 113.87% 91.72%
Cash From Operating Activities -$48.45M -$37.95M -$159.8M
YoY Change 13.74% 22.79% 89.34%
INVESTING ACTIVITIES
Capital Expenditures $2.277M $2.565M $12.24M
YoY Change -34.42% -397.56% 116.29%
Acquisitions
YoY Change
Other Investing Activities $18.35M $57.57M $39.44M
YoY Change -57.83% -261.45% -138.45%
Cash From Investing Activities $16.07M $55.01M $27.20M
YoY Change -59.86% -250.61% -125.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $19.40M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $1.481M -135.0K $117.2M
YoY Change -0.47% -127.0% -23.84%
NET CHANGE
Cash From Operating Activities -$48.45M -37.95M -$159.8M
Cash From Investing Activities $16.07M 55.01M $27.20M
Cash From Financing Activities $1.481M -135.0K $117.2M
Net Change In Cash -$30.90M 16.92M -$15.42M
YoY Change 2681.55% -125.28% -60.2%
FREE CASH FLOW
Cash From Operating Activities -$48.45M -$37.95M -$159.8M
Capital Expenditures $2.277M $2.565M $12.24M
Free Cash Flow -$50.73M -$40.52M -$172.1M
YoY Change 10.11% 34.85% 91.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001549595
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 nrix Net Operating Loss Carryback Period Cares Act
NetOperatingLossCarrybackPeriodCARESAct
P5Y
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-11-30
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--11-30
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-39398
CY2022 dei Entity Registrant Name
EntityRegistrantName
NURIX THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-0838048
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
1700 Owens Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 205
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
CY2022 dei City Area Code
CityAreaCode
415
CY2022 dei Local Phone Number
LocalPhoneNumber
660-5320
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2022 dei Trading Symbol
TradingSymbol
NRIX
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
443500000 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
47273098 shares
CY2022 dei Auditor Firm
AuditorFirmId
238
CY2022 dei Auditor Name
AuditorName
PricewaterhouseCoopers LLP
CY2022 dei Auditor Location
AuditorLocation
San Jose, California
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64474000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80506000 usd
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
244667000 usd
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
215214000 usd
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
0 usd
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
6000000 usd
CY2022Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
0 usd
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
204000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9308000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9194000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
318449000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
311118000 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
63879000 usd
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
137189000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
12345000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
14005000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17163000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11340000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
286000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4022000 usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2833000 usd
CY2022Q4 us-gaap Assets
Assets
416759000 usd
CY2021Q4 us-gaap Assets
Assets
476771000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5064000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6650000 usd
CY2022Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
22428000 usd
CY2021Q4 nrix Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
14549000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5530000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3847000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
37633000 usd
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
41212000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
70655000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
66258000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6434000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9189000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
35974000 usd
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
59022000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
113063000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
134469000 usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47172299 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47172299 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44664371 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44664371 shares
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
47000 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
45000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
709220000 usd
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
563757000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4319000 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-608000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401252000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220892000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
303696000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
416759000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
476771000 usd
CY2022 us-gaap Revenues
Revenues
38627000 usd
CY2021 us-gaap Revenues
Revenues
29750000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
184497000 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
116434000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37997000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
31202000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
222494000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
147636000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-183867000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-117886000 usd
CY2022 us-gaap Interest And Other Income
InterestAndOtherIncome
3507000 usd
CY2021 us-gaap Interest And Other Income
InterestAndOtherIncome
823000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-180360000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-117063000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-117194000 usd
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.71
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.71
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.73
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.73
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48607990 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48607990 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42895383 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42895383 shares
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-117194000 usd
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3711000 usd
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-695000 usd
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-184071000 usd
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-117889000 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
290269000 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
150157000 usd
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1666000 usd
CY2021 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
0 usd
CY2021 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
239000 usd
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2060000 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15800000 usd
CY2021 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-695000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-117194000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
342302000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
94759000 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19328000 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1078000 usd
CY2022 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
0 usd
CY2022 nrix Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions
145000 usd
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1955000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28200000 usd
CY2022 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-3711000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
303696000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-117194000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5349000 usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2790000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
28131000 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
15800000 usd
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-426000 usd
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1706000 usd
CY2022 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-9000 usd
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-128000 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
5459000 usd
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3292000 usd
CY2022 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-201000 usd
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-6000000 usd
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
6000000 usd
CY2022 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
0 usd
CY2021 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-3642000 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1094000 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5442000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
85000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1589000 usd
CY2022 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-26627000 usd
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
14250000 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-4871000 usd
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-5144000 usd
CY2022 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
7485000 usd
CY2021 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
6218000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-159807000 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-84365000 usd
CY2022 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
239366000 usd
CY2021 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
348497000 usd
CY2022 nrix Proceeds From Sales Of Investments
ProceedsFromSalesOfInvestments
0 usd
CY2021 nrix Proceeds From Sales Of Investments
ProceedsFromSalesOfInvestments
6994000 usd
CY2022 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
278808000 usd
CY2021 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
238913000 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12244000 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5661000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
27198000 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-108251000 usd
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
94759000 usd
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19400000 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
150157000 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1078000 usd
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1666000 usd
CY2022 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
1955000 usd
CY2021 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
2060000 usd
CY2022 nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
0 usd
CY2021 nrix Payments For Repurchase Of Unvested Early Exercised Stock Options
PaymentsForRepurchaseOfUnvestedEarlyExercisedStockOptions
1000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
117192000 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
153882000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-15417000 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38734000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
119526000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65375000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
481000 usd
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1373000 usd
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2505000 usd
CY2022 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
69000 usd
CY2021 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
0 usd
CY2022 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
145000 usd
CY2021 nrix Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
239000 usd
CY2022 nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
72000 usd
CY2021 nrix Deferred Issuance Costs Recognized Related To Equity Financing
DeferredIssuanceCostsRecognizedRelatedToEquityFinancing
0 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64474000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80506000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
901000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
286000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
65375000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
80792000 usd
CY2022Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
309100000 usd
CY2022Q4 nrix Working Capital
WorkingCapital
247800000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-401300000 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. On an ongoing basis, management evaluates its estimates, including those related to the useful lives of long-lived assets, the measurement of stock-based compensation, accruals for research and development activities, income taxes and revenue recognition. The Company bases its estimates on historical experience and on other relevant assumptions that are reasonable under the circumstances. Actual results could materially differ from those estimates. Refer to Note 3 for more information regarding the estimates related to revenue recognition.</span></div>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash, cash equivalents and marketable securities. The Company’s marketable securities consist of debt securities issued by highly rated corporate entities, the U.S. federal government or state and local governments. The Company’s exposure to any individual corporate entity is limited by policy. Deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents in highly rated money market funds. During the periods presented, the Company has not experienced any losses on its deposits of cash, cash equivalents or marketable securities.</span></div>
CY2022 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 segment
CY2022 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
900000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
300000 usd
CY2022 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2022 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 usd
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
500000 usd
CY2022Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
500000 usd
CY2021 nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36833000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26219000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19670000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14879000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17163000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11340000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
5300000 usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2800000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
13164000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8854000 usd
CY2022Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
6426000 usd
CY2021Q4 nrix Accrued Contract Research And Lab Supplies
AccruedContractResearchAndLabSupplies
4158000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1250000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
803000 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
85000 usd
CY2021Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
75000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1503000 usd
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
659000 usd
CY2022Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
22428000 usd
CY2021Q4 nrix Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
14549000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Term
DebtSecuritiesAvailableForSaleTerm
P2Y
CY2021Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0 usd
CY2022Q4 nrix Transfers Of Financial Instruments Between Valuation Levels
TransfersOfFinancialInstrumentsBetweenValuationLevels
0 usd
CY2022 nrix Impairment Loss On Investment
ImpairmentLossOnInvestment
0 usd
CY2022Q4 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
57902 sqft
CY2022Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P2Y
CY2021Q3 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
19320 sqft
CY2022Q1 nrix Area Of Office Space Leased
AreaOfOfficeSpaceLeased
46434 sqft
CY2022Q1 nrix Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
2 terms
CY2022Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q1 nrix Operating Lease Rent Payable Per Month
OperatingLeaseRentPayablePerMonth
205000 usd
CY2022Q1 nrix Percentage Of Increase Of Annual Rent
PercentageOfIncreaseOfAnnualRent
0.03
CY2022Q1 nrix Lessee Operating Lease Liability To Be Paid Year One Per Month
LesseeOperatingLeaseLiabilityToBePaidYearOnePerMonth
154000 usd
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
5900000 usd
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
3800000 usd
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0298
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
6578000 usd
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
4026000 usd
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
5068000 usd
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2371000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
6980000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
7422000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
4330000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2670000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2750000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
22556000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
46708000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
430000 usd
CY2022Q4 nrix Lessee Operating Lease Not Yet Commenced Liability Undiscounted Excess Amount
LesseeOperatingLeaseNotYetCommencedLiabilityUndiscountedExcessAmount
34314000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11964000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
5530000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6434000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11964000 usd
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000 shares
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022 us-gaap Common Stock Voting Rights
CommonStockVotingRights
one
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18016515 shares
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
9476306 shares
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
4500000 usd
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
15900000 usd
CY2022Q4 nrix Share Based Compensation Arrangement By Share Based Payment Award Options Shares Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesSubjectToRepurchase
22246 shares
CY2022Q4 nrix Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Value Of Shares Subject To Repurchase
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExerciseValueOfSharesSubjectToRepurchase
200000 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
11.80
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
21.15
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-180360000 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
79300000 usd
CY2022 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M23D
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
900000 usd
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
700000 usd
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
100000 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-180360000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-117063000 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-117063000 usd
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 usd
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-203000 usd
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 usd
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
334000 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
131000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.059
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.050
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.035
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.045
CY2022 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.020
CY2021 us-gaap Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
-0.012
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.284
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.293
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.001
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
83775000 usd
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41081000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
27096000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
17502000 usd
CY2022Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
19950000 usd
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
21874000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3846000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1054000 usd
CY2022Q4 nrix Deferred Tax Assets Accrued Expenses And Other Liabilities
DeferredTaxAssetsAccruedExpensesAndOtherLiabilities
3797000 usd
CY2021Q4 nrix Deferred Tax Assets Accrued Expenses And Other Liabilities
DeferredTaxAssetsAccruedExpensesAndOtherLiabilities
1896000 usd
CY2022Q4 nrix Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
3199000 usd
CY2021Q4 nrix Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
3436000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
141663000 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
86843000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
138362000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
83517000 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3301000 usd
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
3326000 usd
CY2022Q4 nrix Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
3301000 usd
CY2021Q4 nrix Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
3326000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3301000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
3326000 usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
54800000 usd
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
36100000 usd
CY2022Q4 nrix Net Operating Loss Unutilized Amount
NetOperatingLossUnutilizedAmount
400000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10300000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6331000 usd
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5361000 usd
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 usd
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
48607990 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42895383 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42895383 shares
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.71
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000 usd
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
3930000 usd
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2282000 usd
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
0 usd
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
1313000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10261000 usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
6331000 usd
CY2022 nrix Income Tax Decrease In Tax Credits Research Amount
IncomeTaxDecreaseInTaxCreditsResearchAmount
1300000 usd
CY2021 nrix Net Operating Loss Carryback Refund Claim Cares Act
NetOperatingLossCarrybackRefundClaimCARESAct
19600000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-180360000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-117194000 usd
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
48607990 shares
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.71
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.73
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.73
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9187221 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6008228 shares

Files In Submission

Name View Source Status
nrix-20221130_lab.xml Edgar Link unprocessable
0001549595-23-000021-index-headers.html Edgar Link pending
0001549595-23-000021-index.html Edgar Link pending
0001549595-23-000021.txt Edgar Link pending
0001549595-23-000021-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nrix-20221130.htm Edgar Link pending
nrix-20221130.xsd Edgar Link pending
nrix-20221130xexx231.htm Edgar Link pending
nrix-20221130xexx311.htm Edgar Link pending
nrix-20221130xexx312.htm Edgar Link pending
nrix-20221130xexx321.htm Edgar Link pending
nrix-20221130xexx43.htm Edgar Link pending
nrix-20221130_g1.jpg Edgar Link pending
nrix-20221130_g10.jpg Edgar Link pending
nrix-20221130_g11.jpg Edgar Link pending
nrix-20221130_g12.jpg Edgar Link pending
nrix-20221130_g13.jpg Edgar Link pending
nrix-20221130_g14.jpg Edgar Link pending
nrix-20221130_g15.jpg Edgar Link pending
nrix-20221130_g16.jpg Edgar Link pending
nrix-20221130_g17.jpg Edgar Link pending
nrix-20221130_g18.jpg Edgar Link pending
nrix-20221130_g19.jpg Edgar Link pending
nrix-20221130_g2.jpg Edgar Link pending
nrix-20221130_g20.jpg Edgar Link pending
nrix-20221130_g21.jpg Edgar Link pending
nrix-20221130_g22.jpg Edgar Link pending
nrix-20221130_g23.jpg Edgar Link pending
nrix-20221130_g24.jpg Edgar Link pending
nrix-20221130_g25.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nrix-20221130_cal.xml Edgar Link unprocessable
nrix-20221130_def.xml Edgar Link unprocessable
nrix-20221130_g26.jpg Edgar Link pending
nrix-20221130_g27.jpg Edgar Link pending
nrix-20221130_g28.jpg Edgar Link pending
nrix-20221130_g3.jpg Edgar Link pending
nrix-20221130_g4.jpg Edgar Link pending
nrix-20221130_g5.jpg Edgar Link pending
nrix-20221130_g6.jpg Edgar Link pending
nrix-20221130_g7.jpg Edgar Link pending
nrix-20221130_g8.jpg Edgar Link pending
nrix-20221130_g9.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
nrix-20221130_pre.xml Edgar Link unprocessable
nrix-20221130_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending